latest updates

friends & family

Scinovia is transitioning from investors to sales to capitalize growth:

Announcing a special “Friends & Family” round that closes in a few weeks.

2-click investingcash or IRA | IRA transfer


Management targets ROI:
4X – 10X
PPM for details**


14% semi-annual
10% monthly annuity

*   Request password: or contact form.
** Private Placement Memorandum is available for download during stock purchase process

FDA class I

Scinovia Corp is now a Registered Manufacturer with FDA, and

VU-FLOW™ is FDA listed as a Class I exempt device

MET Labs certification

Scinovia Corp’s manufacturing facility and its product VU-FLOW™ earn Eurofins MET Labs certification to UL 61010 (April 2019).

global market report

Inkwood Research recognizes Scinovia as an emerging disruptor to fast growing global market of blood flow measurement devices, where doctors spent $500M last year … CONTINUE TO ARTICLE

Inkwood Research Interview

inkwood research interviews Scinovia CEO

Inkwood Research interviews Scinovia CEO, Jim Sund, about their NOVIA™ platform, its 1st product line VU-FLOW™ and competitive advantages … CONTINUE TO ARTICLE